Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Aug 5;8(8):ofab372.
doi: 10.1093/ofid/ofab372. eCollection 2021 Aug.

Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide for Human Immunodeficiency Virus Preexposure Prophylaxis at a Boston Community Health Center

Julia L Marcus  1   2 , Kenneth Levine  2 , Whitney C Sewell  1 , Patricia Solleveld  1   3 , Kenneth H Mayer  2   3 , Douglas S Krakower  1   2   3
Affiliations

Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide for Human Immunodeficiency Virus Preexposure Prophylaxis at a Boston Community Health Center

Julia L Marcus et al. Open Forum Infect Dis. .

Abstract

Background: Efforts to end the human immunodeficiency virus (HIV) epidemic may be threatened if limited preexposure prophylaxis (PrEP) resources are funneled from tenofovir disoproxil fumarate with emtricitabine (TDF/FTC) to tenofovir alafenamide with emtricitabine (TAF/FTC) without proportional clinical benefits.

Methods: The study population was patients at a Boston community health center who were assigned male sex at birth, aged ≥18 years, and prescribed TDF/FTC for PrEP in the 12 months before TAF/FTC approval (October 2019). We determined the frequency of switching to TAF/FTC in the 12 months after approval, including clinically indicated switching (ie, creatinine clearance <60 mL/minute or reduced bone density), potentially unnecessary switching (ie, no indications for switching and no cardiovascular risk factors), and potentially harmful switching (ie, no indications for switching and either obesity or dyslipidemia).

Results: Of 2892 TDF/FTC users, mean age was 38 years, 96.0% were cisgender men, and 78.9% were white. A total of 343 (11.9%) switched to TAF/FTC. Based on documented renal, bone, and cardiovascular risk factors, we identified 24 (7.0%) with clinically indicated switching, 271 (79.0%) with potentially unnecessary switching, and 48 (14.0%) with potentially harmful switching. When indications for switching additionally included hypertension, diabetes, and creatinine clearance 60-70 mL/minute, 27.1% of switching was clinically indicated.

Conclusions: Few who switched to TAF/FTC had documented indications for switching, although some appear to have been switched in anticipation of indications developing. As generic TDF/FTC is further discounted, provider education and patient decision aids are needed to facilitate selection of PrEP medications that is both clinically sound and cost-effective.

Keywords: human immunodeficiency virus; men who have sex with men; preexposure prophylaxis; tenofovir alafenamide; tenofovir disoproxil fumarate.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Centers for Disease Control and Prevention. Effectiveness of prevention strategies to reduce the risk of acquiring or transmitting HIV. 2019. https://www.cdc.gov/hiv/risk/estimates/preventionstrategies.html. Accessed 9 February 2021.
    1. Mayer KH, Molina JM, Thompson MA, et al. . Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. Lancet 2020; 396:239–54. - PMC - PubMed
    1. US Food and Drug Administration. FDA briefing information for the August 7, 2019 meeting of the Antimicrobial Drugs Advisory Committee. 2019. https://www.fda.gov/media/129607/download. Accessed 8 October 2019.
    1. Saag MS, Gandhi RT, Hoy JF, et al. . Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2020 recommendations of the International Antiviral Society–USA panel. JAMA 2020; 324:1651–69. - PMC - PubMed
    1. Descovy (emtricitabine and tenofovir alafenamide). US Food and Drug Administration. 2019. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208215s011lbl.pdf. Accessed 1 March 2021.